Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Freiburg Im Breisgau – page 23

529 clinical trials in Freiburg Im Breisgau, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Freiburg Im Breisgau at a glance
529
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

529 trials in Freiburg Im Breisgau

Open in trial search

Adenocarcinoma pancreas

Not yet recruiting

Study on the Safety and Effectiveness of mFOLFIRINOX with or without BNT321 for Patients with Resected Pancreatic Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:BioNTech SE

Acute graft versus host disease

Not yet recruiting

Study of RLS-0071 in Hospitalized Patients with Steroid-Resistant Acute Graft-versus-Host Disease (aGvHD)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ile-Ala-Leu-Ile-Leu-Glu-Pro-Ile-Cys-Cys-Gln-Glu-Arg-Ala-Ala-(Discrete-Polyethylene Glycol)24
  • Sponsor:Realta Life Sciences Inc.

Pulmonary sarcoidosis

Not yet recruiting

Study on the Effects of OATD-01 for Patients with Active Pulmonary Sarcoidosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methylmorpholino)Piperidin-1-Yl)-1H- 1,2,4-Triazol-3-Amine
  • Sponsor:Molecure S.A.

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Cholangiocarcinoma

Not yet recruiting

Study of Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Servier Affaires Medicales

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Macular oedema

Not yet recruiting

Study on the Effects of RO7200220 for Patients with Uveitic Macular Edema

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg2 Monoclonal Antibody Against Interleukin-6
  • Sponsor:F. Hoffmann-La Roche AG

HIV infection

Not yet recruiting

Study on HIV-1 Treatment for Patients New to Therapy: Comparing Doravirine/Islatravir with a Drug Combination

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:GPOH gGmbH

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Freiburg Im Breisgau

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer, non-small cell lung cancer, and colon cancer treatments. Studies evaluating new therapeutic approaches for both early-stage and advanced cancers.

  • Breast Cancer Therapy Optimization
  • Advanced Lung Cancer Treatments
  • Gastrointestinal Cancer Research

Emphasis on targeted therapies and combination treatments to improve patient outcomes.

02 Autoimmune Conditions

Research into treatments for psoriatic arthritis, rheumatoid arthritis, and Sjögren's disease. Studies evaluating novel biologics and targeted therapies.

  • Inflammatory Arthritis Management
  • Autoimmune Disease Therapeutics
  • Novel Treatment Approaches

Focus on improving disease control and quality of life for patients with chronic autoimmune conditions.

03 Rare Diseases

Clinical investigations of treatments for spinal muscular atrophy, sickle cell disease, and primary sclerosing cholangitis. Studies aimed at developing innovative therapies.

  • Genetic Disease Treatments
  • Blood Disorders
  • Pediatric Rare Diseases

Dedicated to finding breakthrough treatments for challenging rare conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.